Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Areej El-Jawahri, Alison R Kavanaugh, Joseph A Greer, Vicki Jackson, Jillian Gustin, Alice Mims, Albert Cook, Thomas W. LeBlanc, Amir T. Fathi, Gabriela S. Hobbs, Andrew M. Brunner, Jennifer S Temel

Blood (2024) 144 (Supplement 1): 117.

https://doi.org/10.1182/blood-2024-209628

Published: 2024

Journal Articles

Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression

Orly Leiva, Steven Soo, Nathaniel Smilowitz, Harmony Reynolds, Binita Shah, Samuel Bernard, Michelle Hyunju Lee, Chi-Joan How, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 246.

https://doi.org/10.1182/blood-2024-199120

Published: 2024

Journal Articles

Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)

Blood (2024) 144 (Supplement 1): 16.

https://doi.org/10.1182/blood-2024-199107

Published: 2024

Journal Articles

Risk of Osteoporosis and Osteoporotic Fractures in Patients with Myeloproliferative Neoplasms

Michelle Hyunju Lee, Yating Wang, Angel Cronin, Angela C. Tramontano, Lachelle D. Weeks, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 4560.

https://doi.org/10.1182/blood-2024-201719

Published: 2024

Journal Articles

Clinical Features and Preliminary Investigation of PPM1D-Mutated Myeloproliferative Neoplasms

Hatem A. Ellaithy, Valentina Nardi, Harrison K. Tsai, Carmen Da Silva, Peter G. Miller, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 4525.

https://doi.org/10.1182/blood-2024-207678

Published: 2024

Journal Articles

Factors Associated with Quality of Life Impairments in Patients with Myeloproliferative Neoplasms: Looking Beyond Symptom Burden

Chi-Joan How, Bridget Coffey, Christina M. Dieli-Conwright, Gabriela S. Hobbs, Hermioni L Amonoo, Areej El-Jawahri, Richard Newcomb

Blood (2024) 144 (Supplement 1): 3811.

https://doi.org/10.1182/blood-2024-194829

Published: 2024

Journal Articles

Retrospective Single-Institution Review of Bosutinib Dose Optimization for Efficacy and Safety with Dose Ramp-up and Titration

Jessica Freydman, David Sirignano, Philip C. Amrein, Meghan Bergeron, Andrew M. Brunner, Elsie Foster, Amir T. Fathi, Timothy Aaron Graubert, Hanno Hock, Michelle Hyunju Lee, Jenna Moran, Rupa Narayan, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6591.

https://doi.org/10.1182/blood-2024-203629

Published: 2024

Journal Articles

Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

Chi-Joan How, Yiwen Liu, Kathleen Gallagher, Emma K Logan, Ann Mullally, Donna S. Neuberg, Thomas Reardon, Alyssa Watson, Daniel J. DeAngelo, Rushad Patell, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6644.

https://doi.org/10.1182/blood-2024-194126

Published: 2024

Journal Articles

TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

Rupa Narayan, Ronan T. Swords, Philip C. Amrein, Andrew M. Brunner, Gabriela S. Hobbs, Hanno Hock, Michelle Hyunju Lee, Timothy Aaron Graubert, Amir T. Fathi, Robert P Hasserjian, Valentina Nardi

Blood (2024) 144 (Supplement 1): 6154.

https://doi.org/10.1182/blood-2024-211201

Published: 2024

Journal Articles

Cellular and Serologic Responses to Influenza Vaccination in Myeloproliferative Neoplasm Patients

Chi-Joan How, Stella Nam, Charlene Kok, Sonia Mukherjee, Petra Bachanová, Patrick Reeves, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6563.

https://doi.org/10.1182/blood-2024-210631

Published: 2024

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Response in Patients with Chronic Myelogenous Leukemia (CML) and BCR-ABL 35 Base Pair Intron 8 Insertion (35INS)

Roxana A Portillo, Michelle Hyunju Lee, Harrison K. Tsai, Daniel J DeAngelo, Amir T. Fathi, Rupa Narayan, Marlise R Luskin, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6598.

https://doi.org/10.1182/blood-2024-206655

Published: 2024

Journal Articles

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4569.1.

https://doi.org/10.1182/blood-2024-194550

Published: 2024

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Journal Articles

Incidence, Risk Factors, and Prognostic Implications of Heart Failure Hospitalizations Among Patients with Myeloproliferative Neoplasms

Orly Leiva, Steven Soo, Nathaniel Smilowitz, Harmony Reynolds, Binita Shah, Samuel Bernard, Michelle Hyunju Lee, Chi-Joan How, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 3188.

https://doi.org/10.1182/blood-2024-207586

Published: 2024

Journal Articles

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Andrew M. Brunner, Yiwen Liu, Rupa Narayan, Michelle Hyunju Lee, Philip C. Amrein, Hanno Hock, Gabriela S. Hobbs, Donna S. Neuberg, Timothy Aaron Graubert, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2024-196718

Published: 2024

Journal Articles

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood (2024) 144 (Supplement 1): 659.

https://doi.org/10.1182/blood-2024-193678

Published: 2024

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Nico Gagelmann, Gabriela S. Hobbs, Edoardo Campodonico, Polona Novak, Vaneuza Funke, Vanderson Rocha, Nelson Hamerschlak, Thomas Schroeder, Christina Rautenberg, Linette Bosques, Raffaella Greco, Artur Schneider, Grzegorz Helbig, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2023-191300

Published: 2023

Journal Articles

Psychiatric and Substance Use Disorders Are Independent Predictors of Treatment Response and Outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Combinations

Michelle Hyunju Lee, Jennifer La, Mary T Brophy, Nhan V Do, Camille V. Edwards, Clark Dumontier, Gabriela S. Hobbs, Nathanael R Fillmore

Blood (2023) 142 (Supplement 1): 388.

https://doi.org/10.1182/blood-2023-180915

Published: 2023

Journal Articles

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Joan How, Orly Leiva, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2023-179324

Published: 2023

NARROW

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression

Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)

Risk of Osteoporosis and Osteoporotic Fractures in Patients with Myeloproliferative Neoplasms

Clinical Features and Preliminary Investigation of PPM1D-Mutated Myeloproliferative Neoplasms

Factors Associated with Quality of Life Impairments in Patients with Myeloproliferative Neoplasms: Looking Beyond Symptom Burden

Retrospective Single-Institution Review of Bosutinib Dose Optimization for Efficacy and Safety with Dose Ramp-up and Titration

Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

Cellular and Serologic Responses to Influenza Vaccination in Myeloproliferative Neoplasm Patients

Tyrosine Kinase Inhibitor (TKI) Response in Patients with Chronic Myelogenous Leukemia (CML) and BCR-ABL 35 Base Pair Intron 8 Insertion (35INS)

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Incidence, Risk Factors, and Prognostic Implications of Heart Failure Hospitalizations Among Patients with Myeloproliferative Neoplasms

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Psychiatric and Substance Use Disorders Are Independent Predictors of Treatment Response and Outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Combinations

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only